Back to Results

Roger Perreault, MD

Training + Education Tufts University School of Medicine
Gender Male
Accepted Insurances View Accepted Insurances at Tufts Medical Center

Perreault RE, Fournier CA, Mattingly DA, Junghans RP, Talmo CT. Oral tranexamic acid reduces transfusions in total knee arthroplasty. The Journal of Arthroplasty 32 (10), 2990-2994. PMID: 28757131.
El Fiky A, Perreault RE, McGinnis GJ, Rabin RL. Attenuated expression of interferon-beta and interferon-lambda1 by human alternatively activated macrophages. Human Immunology. 2013, Dec; 74(12): 1524-1530. PMID: 23993990.
Jaffe IZ, Newfell BG, Aronovitz M, Mohammad NN, McGraw AP, Perreault RE, Carmeliet P, Ehsan A, Mendelsohn ME. Placental growth factor mediates aldosterone-dependent vascular injury in mice. Journal of Clinical Investigation. 2010, Nov; 120(11): 3891. PMID: 20921624.
El Fiky A, Perreault RE, Kirschman K, Rabin RL. (March, 2011). Interferon-beta expression is attenuated in a human model of alternatively activated macrophages. 2011 Annual Meeting of the American Academy of Allergy, Asthma, and Immunology; San Francisco, CA, USA.
El Fiky A, Perreault RE, McGinnis GJ, Rabin RL. (September, 2013). Interferon Regulatory Factor 4 (IRF4) mediates IFN-beta and lambda1 expression upon TLR4 and MR challenge in human alternatively activated macrophages. 2013 International Cytokine Society Annual Meeting; San Francisco, CA, USA.
El Fiky A, Perreault RE, Rabin RL. (September, 2012). Type I and III interferon are attenuated in a human in vitro model of alternatively activated macrophages and is mediated by IRF4. 10th Joint Meeting of International Cytokine Society and International Society for Interferon and Cytokine Research; Geneva, CHE.
Perreault RE, Bell C, Robbins C, Mattingly D, Talmo CT. (March, 2017). Oral Tranexamic Acid Reduces Transfusions in Total Knee Arthroplasty. 2017 American Academy of Orthopaedic Surgeons Annual Meeting; San Diego, CA, USA.

Roger E. Perreault, MD graduated from Middlebury College with a Bachelor of Arts in Chemistry. He worked in the Jaffe Laboratory at the Molecular Cardiology Research Institute at Tufts Medical Center in Boston, MA, investigating the molecular mechanisms underlying the vasoprotective effects of mineralocorticoid receptor antagonists. He then studied interferon-alpha subtype gene expression by alternatively activated (M2) macrophages during his Oak Ridge Institute Fellowship in Immunobiochemistry at the Food and Drug Administration.
He worked with JDC Medical Director Rick Hodes, MD, MACP and the Missionaries of Charity in Addis Ababa, Ethiopia before attending Tufts University School of Medicine, where he demonstrated a reduction in transfusion requirements in patients treated with orally administered tranexamic acid. He is currently a member of the Wallingford Lab at the Mother Infant Research Institute at Tufts Medical Center, where his research interests include the pathophysiologic mechanisms underlying ectopic vascular calcification, phosphate transporter biology, and the relationship between aberrant developmental vascular morphology and organogenesis.

The research focus in the Wallingford Lab is development and pathophysiology of the placenta. The placenta contains highly specialized vasculature that mediates interaction between maternal and fetal circulatory systems during pregnancy. Impaired placental growth or function can have dire impact on maternal and fetal health. In the long-term, Dr. Wallingford aims to advance knowledge of placental development and assist in the development of early diagnostics and novel therapeutics for disorders of placental insufficiency or dysfunction. Specific areas of interest include maternal-fetal phosphate transport biology, morphogenetic analysis of placentation, and development of new approaches to assess vascular structure and function at the maternal-fetal interface.